Company: EDSA
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001171843-25-000866
Chunk: 37

Company: Edesa Biotech, Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 1
Chunk 37
---
			$
			(1,678,451
			)

			Adjustments for:

			Depreciation and amortization

			43,109

			45,031

			Share-based compensation

			81,183

			184,357

			Changes in working capital items:

			Accounts and other receivable

			(97,692
			)

			(99,585
			)

			Prepaid expenses and other current assets

			43,636

			38,664

			Accounts payable and accrued liabilities

			29,814

			103,456

			Net cash used in operating activities

			(1,517,203
			)

			(1,406,528
			)

			Cash flows from financing activities:

			Proceeds from issuance of common shares

			626,760

			315,201

			Proceeds from issuance of Series A-1 preferred shares and warrants

			1,540,820

			-

			Payments for issuance costs of common shares and warrants

			(96,035
			)

			(9,459
			)

			Net cash provided by financing activities

			2,071,545

			305,742

			Effect of exchange rate changes on cash and cash equivalents

			(28,160
			)

			7,176

			Net change in cash and cash equivalents

			526,182

			(1,093,610
			)

			Cash and cash equivalents, beginning of period

			1,037,320

			5,361,397

			Cash and cash equivalents, end of period

			$
			1,563,502

			$
			4,267,787

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

5

Edesa Biotech, Inc.

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity

			Shares #

			Common Shares

			Series A-1 Preferred Shares

			Additional Paid-in Capital

			Accumulated Other Comprehensive Loss

			Accumulated Deficit

			Total Shareholders' Equity

			Three Months Ended December 31, 2024

			Balance - September 30, 202